Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
Gynecologic Oncology
|
July 2, 2023
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203
Andre Konski, Snehal Deshmukh, Ann H Klopp, et al.
Advances in Radiation Oncology
|
September 12, 2018
Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities
Canhua Xiao, Jennifer Moughan, Benjamin Movsas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W Robert Lee, James J Dignam, Mahul B Amin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 3, 2023
Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415
Jinbing Bai, Stephanie L Pugh, Ronald Eldridge, et al.
Gynecologic Oncology
|
May 21, 2019
Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy
Karen M Gil, Stephanie L Pugh, Ann H Klopp, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer
Himanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2020
Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study
Anamaria R Yeung, Stephanie L Pugh, Ann H Klopp, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 25, 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415
Maria Thor, Joseph O Deasy, Rebecca Paulus, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 21, 2021
Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer
Canhua Xiao, Andrew H Miller, Gang Peng, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)
Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
Gynecologic Oncology
|
July 2, 2023
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203
Andre Konski, Snehal Deshmukh, Ann H Klopp, et al.
Advances in Radiation Oncology
|
September 12, 2018
Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities
Canhua Xiao, Jennifer Moughan, Benjamin Movsas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W Robert Lee, James J Dignam, Mahul B Amin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 3, 2023
Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415
Jinbing Bai, Stephanie L Pugh, Ronald Eldridge, et al.
Gynecologic Oncology
|
May 21, 2019
Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy
Karen M Gil, Stephanie L Pugh, Ann H Klopp, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer
Himanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2020
Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study
Anamaria R Yeung, Stephanie L Pugh, Ann H Klopp, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 25, 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415
Maria Thor, Joseph O Deasy, Rebecca Paulus, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 21, 2021
Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer
Canhua Xiao, Andrew H Miller, Gang Peng, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)
Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
Page
of 9